Transgenomic Aims to Widely License PCR Tech While Prepping Cancer Test Kits for Market | GenomeWeb

NEW YORK (GenomeWeb) – Following the planned launch of a series of liquid biopsy cancer tests over the next six months, Transgenomic is aiming to broadly license the multiplexed PCR-based technology that powers the products to instrument and reagent firms, according to President and CEO Paul Kinnon.

Once it has done so, Kinnon told GenomeWeb this week, the firm plans to decide whether there are any applications or specific disease areas in which it wants to maintain exclusivity with the technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.